Market Size of Global Oxytocin Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.40 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Oxytocin Market Analysis
The oxytocin market is expected to record a CAGR of 5.4% over the forecast period.
COVID-19 significantly impacted the oxytocin market and the overall healthcare industry during the initial phase. For instance, as per the article published in May 2022 under the title "Oxytocin, the Panacea for Long-COVID? A Review", in the study," researchers evaluated the underlying mechanisms for long-COVID and how the oxytocinergic neurons are likely to be affected by SARS-CoV-2 leading to a reduction in plasma oxytocin (OXT). The study also identified a potential mechanism for long-COVID that involves OXT dysfunction. Furthermore, the article published in August 2021 titled" Covid and Oxytocin: Looking for Microbial Symbiosis' stated that the oxytocin hormone has anti-inflammatory and antioxidant protective effects and has received particular attention due to the pandemic of COVID-19. Hence, as per the factors mentioned above, COVID-19 significantly impacted the oxytocin market.
Factors driving the market growth include the increasing prevalence of pregnancy complications, rising births globally, and growing awareness of induced labor and breastfeeding. For instance, as per the December 2021 update from United Nations International Children's Emergency Fund (UNICEF), an estimated 140 million children were born in 2021. Furthermore, as per the August 2021 update from International Institute for Sustainable Development, the global population is projected to increase to 9.7 billion by 2050. This level represents a nearly 24% increase over 2020. Because of the increased birth rate and population levels, there is a high chance for growth of the oxytocin market since oxytocin is advised for antepartum and postpartum pregnancy.
Moreover, the presence of competitors, new developments associated with oxytocin, and collaborations boost the market growth. For instance, per the January 2021 update, Tonix Pharmaceuticals entered a licensing agreement with Katana Pharmaceuticals for its intranasal potentiated oxytocin to expand its use in metabolic disorders, especially insulin resistance, diabetes, and obesity. The licensing deal is an addition to the company's original purchase of oxytocin-potentiated therapy from Trigemina in June 2020, with preclinical data demonstrating the efficacy of the intranasal oxytocin product TNX-1900 in disorders of the central nervous system, with migraine chosen as the lead indication by Tonix. These oxytocin-related collaborative ventures and partnerships open the way for various indications, supporting the market's growth over the forecast period.
Furthermore, the application of oxytocin in pregnancy boosts the market growth, for instance, as per the article published in July 2020 titled "Role of Oxytocin in Prevention of Postpartum Hemorrhage in Unplanned Out-of-Hospital Deliveries Treated By Emergency Medical Services" in Finland, postpartum hemorrhage following unplanned out-of-hospital deliveries was prevented by intramuscular or intravenous oxytocin administration. Rising disposable incomes, especially in developing countries, increasing awareness regarding pregnancy care products among women, an increase in the literacy rate of women, and an increase in well-developed distribution channels for oxytocin products are the major factors driving the growth of the oxytocin market.
As per the factors above, the oxytocin market will likely grow over the forecast period. However, stringent regulations and the high cost of oxytocin drugs associated with the drug restrain the market growth.
